Lab results are too important to go anywhere else

Beaumont Laboratory

BCR/ABL1, Major (p210), Quantitation

BCR Quantitation By RT-PCR, EPIC: LAB7136, SOFT: G210G


Samples should be drawn as early in the day as possible, so they can be delivered to the Laboratory the same day.

Specimen Collection Criteria

Collect: 10 mL whole blood in Lavender-top EDTA. (Min: 5.0 mL)

A copy of the requisition must be sent with the specimen. 

FedEx Shipping Instructions

Transport 10 mL whole blood (minimum: 5 mL), refrigerated. Do not freeze specimens.

Click here for complete shipping instructions.

Physician Office/Drawsite Specimen Preparation

Do not freeze specimens. Maintain whole blood at room temperature (20-26°C or 68-78.8°F), or refrigerate (2-8°C or 36-46°F) if the specimen will not be received in the laboratory within 6 hours of collection.

Preparation for Courier Transport

Transport: Maintain whole blood at room temperature (20-26°C or 68-78.8°F) or refrigerate (2-8°C or 36-46°F) if the specimen will not be received in the laboratory within 6 hours of collection. (Min: 5.0 mL)

Rejection Criteria

  • Frozen specimens.
  • Unlabeled tubes.
  • Specimens collected in heparin (Green-top), clot tubes (Red-top), ACD anti-coagulant tubes, or SST tubes.


Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 6 hours
Refrigerated (2-8°C or 36-46°F): 48 hours
Frozen (-20°C/-4°F or below): Unacceptable

Specimen Storage in Department Prior to Disposal:

Refrigerated (2-8°C or 36-46°F): 7 days


Royal Oak Clinical Molecular Pathology Laboratory.


Once per week.
Results available within 7-14 days.

Reference Range

Negative (no gene rearrangement detected).

Test Methodology

RNA extraction from whole blood and BCR-ABL fusion transcript and quantitation analysis using real-time reverse transcriptase - polymerase chain reaction (RT-qPCR).


The BCR-ABL fusion transcript quantitation is normalized by calculating the relative ratio to normal ABL transcript. The presence of detectable BCR-ABL transcript confirms the existence of persistent transcriptionally active CML (chronic myeloid leukemia) cells.

Clinical Utility

  • This quantitative test is used for monitoring therapy response to tyrosine kinase inhibitors, by serial measurement of CML-specific transcripts (p210; b2a2, b3a2) as an accurate measure of the total leukemia-cell mass. 
    • This test can only be used if the patient is positive for the b2a2 or b3a2 major (p210) breakpoints.
    • Patient’s positive for alternate breakpoints will be sent to a reference lab.
  • This test is intended for use ONLY on peripheral blood from patients with a previously diagnosed t(9:22) translocation.
  • Peripheral blood specimens from patients with unconfirmed cases of CML or Ph+ ALL should be submitted for BCR/ABL1 Gene Rearrangement testing. 

CPT Code


Test Codes

EPIC: LAB7136, SOFT: G210G

Last Updated


Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.